

PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 62271

Title: Immunotherapy for Pancreatic Cancer

Reviewer's code: 05372169

Position: Peer Reviewer

Academic degree: MD

Professional title: Doctor

Reviewer's Country/Territory: Italy

Author's Country/Territory: South Korea

Manuscript submission date: 2021-01-04

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-01-04 10:01

Reviewer performed review: 2021-01-05 14:42

Review time: 1 Day and 4 Hours

| | |
|---------------------------------|---|
| Scientific quality | <input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish |
| Language quality | <input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection |
| Conclusion | <input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection |
| Re-review | <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No |
| Peer-reviewer statements | Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No |



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
<https://www.wjgnet.com>

SPECIFIC COMMENTS TO AUTHORS

The authors report the role of immune cells in the development of pancreatic cancer, the tumor microenvironment, the cancer immunity cycle, the mechanisms and efficacies of immunotherapeutic drugs in pancreatic cancer, and the response criteria for use in trials aimed at testing immunotherapeutics in a narrative review. Major comments 1. The authors should report how they selected the literature utilized for this review. In particular, this information should be reported in a specific section. 2. A Figure reporting the possible role of immunotherapy in clinical setting is highly appreciated. 3.

In the section entitled Response criteria for use in trials testing immunotherapeutics the authors stated on the last line that a full description of this issue is beyond the scope of this article. I agree with their statement but a brief explanation should be done. 4.

In the section Future prospects the authors report that artificial intelligence can also be applied for aiding selection of target or protocol in an individual patient from numerous combination of a variety of cancer therapies. I do not agree with this conclusion that should be deleted or better explained.

PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 62271

Title: Immunotherapy for Pancreatic Cancer

Reviewer's code: 03479389

Position: Associate Editor

Academic degree: MD, PhD

Professional title: Associate Professor, Director

Reviewer's Country/Territory: Japan

Author's Country/Territory: South Korea

Manuscript submission date: 2021-01-04

Reviewer chosen by: Ya-Juan Ma

Reviewer accepted review: 2021-01-05 11:29

Reviewer performed review: 2021-01-05 14:58

Review time: 3 Hours

| | |
|---------------------------------|---|
| Scientific quality | <input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish |
| Language quality | <input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection |
| Conclusion | <input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection |
| Re-review | <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No |
| Peer-reviewer statements | Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No |

SPECIFIC COMMENTS TO AUTHORS

This review is well written.

PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 62271

Title: Immunotherapy for Pancreatic Cancer

Reviewer's code: 01191922

Position: Editorial Board

Academic degree: MD, PhD

Professional title: Associate Professor, Doctor, Surgeon

Reviewer's Country/Territory: China

Author's Country/Territory: South Korea

Manuscript submission date: 2021-01-04

Reviewer chosen by: Ya-Juan Ma

Reviewer accepted review: 2021-01-05 14:19

Reviewer performed review: 2021-01-07 14:46

Review time: 2 Days

| | |
|---------------------------------|---|
| Scientific quality | <input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input checked="" type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish |
| Language quality | <input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection |
| Conclusion | <input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection |
| Re-review | <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No |
| Peer-reviewer statements | Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No |

SPECIFIC COMMENTS TO AUTHORS

This is a review about immunotherapy for pancreatic cancer. It addresses the role of immune cells in pancreatic cancer, tumor microenvironment, mechanisms and efficacies of immunotherapeutic drugs in pancreatic cancer, and so on. Several concerns are listed as follows. 1. Usually, pancreatic ductal adenocarcinoma is abbreviated as PDAC. The authors should consider this. 2. The description of the figures should be marked as Figure 1A or Figure 1B, instead of just describing as Figure 1 and Fig.1. 3. The manuscript looks more like a general science article, lacking a comprehensive and profound analysis of immunotherapy for pancreatic cancer. For example, it is full of hope for this treatment, but fails to recognize the challenges it faces. 4. Although clinical outcomes of immunotherapies in advanced pancreatic cancer are listed in Table 2, the agents are briefly introduced. The safety and efficacy of these drugs are not analyzed in detail. The side effects of immunotherapeutic agents should not be underestimated, which should be recognized and managed properly in daily clinical practice. 5. Recently, immunotherapy has not only been limited to unresectable or stage IV pancreatic cancer, but also played an important role in neoadjuvant or adjuvant therapy. The information is also very important. 6. Lack of literature annotation in Table 1. 7. Existing literature on immunotherapy for pancreatic cancer is relatively limited. Thus, attentions should be paid to ongoing clinical trials or studies, which are not introduced or summarized in the manuscript.

PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 62271

Title: Immunotherapy for Pancreatic Cancer

Reviewer's code: 03015784

Position: Peer Reviewer

Academic degree: PhD

Professional title: Surgeon

Reviewer's Country/Territory: China

Author's Country/Territory: South Korea

Manuscript submission date: 2021-01-04

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-01-08 03:14

Reviewer performed review: 2021-01-11 12:36

Review time: 3 Days and 9 Hours

| | |
|---------------------------------|---|
| Scientific quality | <input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish |
| Language quality | <input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection |
| Conclusion | <input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection |
| Re-review | <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No |
| Peer-reviewer statements | Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No |

SPECIFIC COMMENTS TO AUTHORS

The paper presents the current status of pancreatic cancer immunotherapy from the molecular mechanism to the clinical application level. The description of the article is systematic and comprehensive. It is a topic of interest to the researchers in this area. Yet some improvement was needed before acceptance for publication. My detailed comments are as follows: 1. The first section described the cellular composition of tumor microenvironment. A more general paragraph may be needed here to help readers understand the complex immune microenvironment of pancreatic cancer. 2. Based on the latest research results, the role of cancer-associated fibroblasts (CAFs) in pancreatic cancer remains controversial[1]. The crosstalk of CAFs and infiltrating leukocytes was not highlighted, which makes the discussion of CAFs in this chapter slightly less logical. They were neither mention in any other part of immunotherapy applications in this article. 3. The figures may be too simple for review articles. More display of cell interactions or immunotherapy methods may make the article easier for readers to understand. 4. The benefits of GVAX were not mention in the description of current status of immunotherapy. The author even mentioned the lower overall survival of GVAX. More evidence may be needed to prove that GVAX is a promising immunotherapy method in the part of future prospects. Reference: 1. Sahai, E., et al., A framework for advancing our understanding of cancer-associated fibroblasts. *Nat Rev Cancer*, 2020. 20(3): p. 174-186.

PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 62271

Title: Immunotherapy for Pancreatic Cancer

Reviewer's code: 00053419

Position: Editorial Board

Academic degree: PhD

Professional title: Professor

Reviewer's Country/Territory: Spain

Author's Country/Territory: South Korea

Manuscript submission date: 2021-01-04

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-01-10 17:01

Reviewer performed review: 2021-01-15 12:46

Review time: 4 Days and 19 Hours

| | |
|---------------------------------|---|
| Scientific quality | <input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish |
| Language quality | <input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection |
| Conclusion | <input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection |
| Re-review | <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No |
| Peer-reviewer statements | Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No |



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

SPECIFIC COMMENTS TO AUTHORS

The authors provide a comprehensive review about pancreatic cancer immunology and immunotherapy options. In my view, the review is timely and although several aspects would deserve a deeper discussion, the most relevant aspects have been nicely pointed out and discussed in a comprehensive manner. As a suggestion, neoantigen discovery and its projection in personalized vaccination might be extended and references to NGS combined with immunopeptidomics analysis could be provided.

RE-REVIEW REPORT OF REVISED MANUSCRIPT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 62271

Title: Immunotherapy for Pancreatic Cancer

Reviewer's code: 05372169

Position: Peer Reviewer

Academic degree: MD

Professional title: Doctor

Reviewer's Country/Territory: Italy

Author's Country/Territory: South Korea

Manuscript submission date: 2021-01-04

Reviewer chosen by: Jia-Ru Fan

Reviewer accepted review: 2021-02-03 06:05

Reviewer performed review: 2021-02-03 06:58

Review time: 1 Hour

| | |
|---------------------------------|---|
| Scientific quality | <input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish |
| Language quality | <input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection |
| Conclusion | <input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection |
| Peer-reviewer statements | Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No |

SPECIFIC COMMENTS TO AUTHORS

The authors answered to the comments of the reviewers and I have no further comments

RE-REVIEW REPORT OF REVISED MANUSCRIPT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 62271

Title: Immunotherapy for Pancreatic Cancer

Reviewer's code: 03015784

Position: Peer Reviewer

Academic degree: PhD

Professional title: Surgeon

Reviewer's Country/Territory: China

Author's Country/Territory: South Korea

Manuscript submission date: 2021-01-04

Reviewer chosen by: Jia-Ru Fan

Reviewer accepted review: 2021-02-05 01:28

Reviewer performed review: 2021-02-06 09:23

Review time: 1 Day and 7 Hours

| | |
|---------------------------------|---|
| Scientific quality | <input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish |
| Language quality | <input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection |
| Conclusion | <input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection |
| Peer-reviewer statements | Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No |

SPECIFIC COMMENTS TO AUTHORS

The authors have revised all the suggestions. The paper is suggested to be accepted.